I have high blood pressure and the drug I was taking apparently can cause cancer cells to better adapt to the HT treatment I am undergoing. This was brought to my attention and my PCP doctor was not aware of it. I haven't spoken to my oncologist yet, but I brought the report below to my doctor and he immediately change by my blood pressure meds to an ACE inhibitor. He is doing more research on it but said the preliminary info is that the study below is correct. I've included it below so that if anyone has high blood pressure and is on HT they can be aware of the possibility that they are taking a medication that could shorten the effects of the HT.
Ca-channel blockers blunt androgen ablation PSA response
Myrick SE, Panov AV, Graham SD, Jr., et al.
J Urol 159:132A, 1998.
Objective: Changes in intracellular calcium concentration and levels
of calcium-dependent nuclease activity are important mediators of
apoptosis in prostate epithelium. Pharmacological blockade of calciurn
channels may be expected to interfere with androgen ablation therapy
of prostate cancer. We report the effect of calcium-channel blockers
on PSA response to GnRH agonists in prostate cancer patients.
Methods: A cohort of patients was identified that had been treated
with leupron and/or goserelin for prostate cancer. This cohort was
then analyzed for concomitant calcium channel blocker treatment.
Pharmacy and laboratory records were reviewed. Results of patients who
had PSA values checked within one year following first dose of GnRH
agonists were tabulated. No clinical correlation was made.
Results: Twenty six patients not on a calcium-channel blocker while
first given a GnRH agonist showed a first PSA average of 3, PSA nadir
1.75. Twenty-six comparable patients on a calcium-chamel blocker when
first given a GnRH agonist showed an initial post-treatment PSA value
average of 17, PSA nadir 10.2. The differences in both first PSA and
PSA nadir was significant (p = 0.04 and 0.02, respectively). Prior to
treatment, PSA values in the two groups were similar at 30.9 and 37.8.
The proportion of patients achieving a PSA nadir less than or equal to
0.4 within I year was 12/26 (46%) for patients not on calcium channel
blockers, 7/26 27% for patients an calcium channel blockers.
Conclusion: Calcium channel blocker medications reduce the number of
prostate cancer patients responding to androgen ablation by GnRH
agonists as measured by PSA response.
Age 45 (44 when Dx)
Pre-op PSA was 19.8
Surgery on Feb 16, 2007
Post-Op Pathology was poor: Gleason 4+3=7, 4 positive margins, Stage pT3b (Stage III)
HT began in May, '07 with Lupron and Casodex 50mg
IMRT radiation for 38 Treatments ending August 3, '07
My PSA did drop out after surgery to undetectable. It has not returned and I will continue HT until January '08.
My Life is supported very well by family and friends like you all.